Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.
about
Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometryInsulin resistance in Alzheimer's disease.Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene DoseHippocampal atrophy varies by neuropsychologically defined MCI among men in their 50sAPOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.A novel cortical thickness estimation method based on volumetric Laplace-Beltrami operator and heat kernel.Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementiaInfluence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study.The Structural and Functional Connectome and Prediction of Risk for Cognitive Impairment in Older AdultsProtein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease PathologyDementia Coding, Workup, and Treatment in the VA New England Healthcare System.Induced Pluripotent Stem Cells Derived from Alzheimer's Disease Patients: The Promise, the Hope and the Path Ahead.Conformal invariants for multiply connected surfaces: Application to landmark curve-based brain morphometry analysis.Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β.
P2860
Q34615211-E6421453-03F9-4BEE-A8F6-BBEF60F04A6EQ34622157-CCCBCE3A-8FE9-4EE5-89A4-4F8CC9DD8B59Q34806627-996AD0E4-DD1D-4CF9-9847-24217C8A582DQ35133348-BCAE705D-26AC-49BD-8635-760C9361B8EAQ35276365-672B58AC-B1FB-438C-A155-897BDCF56FC3Q35514325-396D38FA-9D7A-4E0F-8EE6-FDCA65B6803EQ35977798-66FDBD9B-EA5E-4345-9222-EF3B83BD7655Q35985867-E9CA0D8C-DF1C-4AC3-9857-318E13090F68Q36733387-91DF176A-0CFE-4DD7-876E-E7EFB4B282AAQ37053850-C1F6C40A-1C5B-4B70-8A69-D422A6D92F24Q37632067-1FB3B89D-4626-48FF-B539-6C7027783FD2Q38559734-753D8501-0718-456A-A0AE-67B289C03F3FQ39378987-79F0E3C6-5DE2-4CE9-B858-2E8D552DDB92Q41444056-1AE3A8CE-DC82-46AC-87E4-B4B00910E53FQ41691372-2E51A52D-6A2C-4A8B-B7A0-293167D58E87Q52691877-54E434AA-A6E3-4D08-B3C9-ABA5760CD209
P2860
Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Characterizing the preclinical ...... f presymptomatic intervention.
@ast
Characterizing the preclinical ...... f presymptomatic intervention.
@en
Characterizing the preclinical ...... f presymptomatic intervention.
@nl
type
label
Characterizing the preclinical ...... f presymptomatic intervention.
@ast
Characterizing the preclinical ...... f presymptomatic intervention.
@en
Characterizing the preclinical ...... f presymptomatic intervention.
@nl
prefLabel
Characterizing the preclinical ...... f presymptomatic intervention.
@ast
Characterizing the preclinical ...... f presymptomatic intervention.
@en
Characterizing the preclinical ...... f presymptomatic intervention.
@nl
P2860
P356
P1476
Characterizing the preclinical ...... f presymptomatic intervention.
@en
P2093
Richard J Caselli
P2860
P304
P356
10.3233/JAD-2012-129026
P478
33 Suppl 1
P577
2013-01-01T00:00:00Z